Skip Navigation
Skip to contents

JLC : Journal of Liver Cancer

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
5 "Classification"
Filter
Filter
Article category
Publication year
Review Articles
Recent updates on the classification of hepatoblastoma according to the International Pediatric Liver Tumors Consensus
Se Un Jeong, Hyo Jeong Kang
J Liver Cancer. 2022;22(1):23-29.   Published online March 17, 2022
DOI: https://doi.org/10.17998/jlc.2022.02.24
  • 6,577 Views
  • 521 Downloads
  • 3 Citations
AbstractAbstract PDF
Hepatoblastoma is the most common pediatric liver malignancy and usually occurs within the first 3 years of life. In recent years, the overall incidence of hepatoblastoma has exhibited the greatest increase among all pediatric malignancies worldwide. The diagnosis of hepatoblastoma may be challenging due to the lack of a current consensus classification system. The International Pediatric Liver Tumors Consensus introduced guidelines and a consensus classification for the diagnosis of hepatoblastoma as either epithelial or mixed epithelial and mesenchymal and in the updated 5th edition of the World Health Organization Classification of Digestive System Tumors.

Citations

Citations to this article as recorded by  
  • Tumor‐associated macrophages: The key player in hepatoblastoma microenvironment and the promising therapeutic target
    Ahmad Adawy, Yoshihiro Komohara, Taizo Hibi
    Microbiology and Immunology.2024;[Epub]     CrossRef
  • Adult hepatoblastoma: making the challenging distinction from hepatocellular carcinoma
    Allison Kaye L. Pagarigan, Paulo Giovanni L. Mendoza
    Journal of Liver Cancer.2023; 23(1): 219.     CrossRef
  • Advances in Histological and Molecular Classification of Hepatocellular Carcinoma
    Joon Hyuk Choi, Swan N. Thung
    Biomedicines.2023; 11(9): 2582.     CrossRef
Close layer
Histopathological Variants of Hepatocellular Carcinomas: an Update According to the 5th Edition of the WHO Classification of Digestive System Tumors
Haeryoung Kim, Mi Jang, Young Nyun Park
J Liver Cancer. 2020;20(1):17-24.   Published online March 31, 2020
DOI: https://doi.org/10.17998/jlc.20.1.17
  • 15,100 Views
  • 1,042 Downloads
  • 29 Citations
AbstractAbstract PDF
Hepatocellular carcinoma (HCC) is heterogeneous in pathogenesis, phenotype and biological behavior. Various histopathological features of HCC had been sporadically described, and with the identification of common molecular alterations of HCC and its genomic landscape over the last decade, morpho-molecular correlation of HCC has become possible. As a result, up to 35% of HCCs can now be classified into histopathological variants, many of which have unique molecular characteristics. This review will provide an introduction to the variously described histopathological variants of HCC in the updated WHO Classification of Digestive System Tumors.

Citations

Citations to this article as recorded by  
  • Computational Pathology: A Survey Review and The Way Forward
    Mahdi S. Hosseini, Babak Ehteshami Bejnordi, Vincent Quoc-Huy Trinh, Lyndon Chan, Danial Hasan, Xingwen Li, Stephen Yang, Taehyo Kim, Haochen Zhang, Theodore Wu, Kajanan Chinniah, Sina Maghsoudlou, Ryan Zhang, Jiadai Zhu, Samir Khaki, Andrei Buin, Fatemeh
    Journal of Pathology Informatics.2024; : 100357.     CrossRef
  • Characterization of lymphocyte‐rich hepatocellular carcinoma and the prognostic role of tertiary lymphoid structures
    Bokyung Ahn, Hee‐Sung Ahn, Jinho Shin, Eunsung Jun, Eun‐Young Koh, Yeon‐Mi Ryu, Sang‐Yeob Kim, Chang Ohk Sung, Ju Hyun Shim, JeongYeon Hong, Kyunggon Kim, Hyo Jeong Kang
    Liver International.2024; 44(5): 1202.     CrossRef
  • Clinical‐Radiologic Morphology‐Radiomics Model on Gadobenate Dimeglumine‐Enhanced MRI for Identification of Highly Aggressive Hepatocellular Carcinoma: Temporal Validation and Multiscanner Validation
    Wanjing Zheng, Xiaodan Chen, Meilian Xiong, Yu Zhang, Yang Song, Dairong Cao
    Journal of Magnetic Resonance Imaging.2024;[Epub]     CrossRef
  • Diagnostic Model for Proliferative HCC Using LI‐RADS: Assessing Therapeutic Outcomes in Hepatectomy and TKI‐ICI Combination
    Mengtian Lu, Zuyi Yan, Qi Qu, Guodong Zhu, Lei Xu, Maotong Liu, Jifeng Jiang, Chunyan Gu, Ying Chen, Tao Zhang, Xueqin Zhang
    Journal of Magnetic Resonance Imaging.2024;[Epub]     CrossRef
  • A Post-International Gastrointestinal Cancers’ Conference (IGICC) Position Statements
    Suayib Yalcin, Sahin Lacin, Ahmed Kaseb, Bora Peynircioğlu, Murat Cantasdemir, Barbaros Çil, Pervin Hurmuz, Ahmet Doğrul, Murat Bozkurt, Hüseyin Abali, Okan Akhan, Halis Şimşek, Berksoy Sahin, Faruk Aykan, İdris Yücel, Gürkan Tellioğlu, Fatih Selçukbirici
    Journal of Hepatocellular Carcinoma.2024; Volume 11: 953.     CrossRef
  • The impact of matrix stiffness on hepatic cell function, liver fibrosis, and hepatocellular carcinoma—Based on quantitative data
    Kiyoon Min, Sathish Kumar Karuppannan, Giyoong Tae
    Biophysics Reviews.2024;[Epub]     CrossRef
  • Low-Baseline PD1+ Granulocytes Predict Responses to Atezolizumab–Bevacizumab in Hepatocellular Carcinoma
    Catia Giovannini, Fabrizia Suzzi, Francesco Tovoli, Mariangela Bruccoleri, Mariarosaria Marseglia, Eleonora Alimenti, Francesca Fornari, Massimo Iavarone, Fabio Piscaglia, Laura Gramantieri
    Cancers.2023; 15(6): 1661.     CrossRef
  • Non-alcoholic fatty liver disease: the pathologist’s perspective
    Wei-Qiang Leow, Anthony Wing-Hung Chan, Paulo Giovanni L. Mendoza, Regina Lo, Kihan Yap, Haeryoung Kim
    Clinical and Molecular Hepatology.2023; 29(Suppl): S302.     CrossRef
  • 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

    Journal of Liver Cancer.2023; 23(1): 1.     CrossRef
  • Three-dimensional multifrequency magnetic resonance elastography improves preoperative assessment of proliferative hepatocellular carcinoma
    Guixue Liu, Di Ma, Huafeng Wang, Jiahao Zhou, Zhehan Shen, Yuchen Yang, Yongjun Chen, Ingolf Sack, Jing Guo, Ruokun Li, Fuhua Yan
    Insights into Imaging.2023;[Epub]     CrossRef
  • Lymphocyte-Rich Hepatocellular Carcinoma with Multiple Lymphadenopathy and Positive Epstein–Barr Virus Encoding Region
    Pin-Yi Wang, Yu-Hsuan Kuo, Ming-Jen Sheu, Hsing-Tao Kuo, Wen-Ying Lee, Yu-Ting Kuo, Su-Hung Wang, Zu-Yau Lin
    Case Reports in Hepatology.2023; 2023: 1.     CrossRef
  • Genome-Wide Extrachromosomal Circular DNA Profiling of Paired Hepatocellular Carcinoma and Adjacent Liver Tissues
    Jianyu Ye, Peixin Huang, Kewei Ma, Zixin Zhao, Ting Hua, Wenjing Zai, Jieliang Chen, Xiutao Fu
    Cancers.2023; 15(22): 5309.     CrossRef
  • Proliferative hepatocellular carcinomas in cirrhosis: patient outcomes of LI-RADS category 4/5 and category M
    Subin Heo, Hyo Jeong Kang, Sang Hyun Choi, Sehee Kim, Youngeun Yoo, Won-Mook Choi, So Yeon Kim, Seung Soo Lee
    European Radiology.2023; 34(5): 2974.     CrossRef
  • Cellular heterogeneity and plasticity in liver cancer
    Lo-Kong Chan, Yu-Man Tsui, Daniel Wai-Hung Ho, Irene Oi-Lin Ng
    Seminars in Cancer Biology.2022; 82: 134.     CrossRef
  • MRI features of histologic subtypes of hepatocellular carcinoma: correlation with histologic, genetic, and molecular biologic classification
    Ja Kyung Yoon, Jin-Young Choi, Hyungjin Rhee, Young Nyun Park
    European Radiology.2022; 32(8): 5119.     CrossRef
  • Variant Hepatocellular Carcinoma Subtypes According to the 2019 WHO Classification: An Imaging-Focused Review
    Liang Meng Loy, Hsien Min Low, Jin-Young Choi, Hyungjin Rhee, Chin Fong Wong, Cher Heng Tan
    American Journal of Roentgenology.2022; 219(2): 212.     CrossRef
  • Paraneoplastic syndromes in hepatocellular carcinoma: a review
    Yuki Ong, Cheong Wei Terence Huey, Vishalkumar Girishchandra Shelat
    Expert Review of Gastroenterology & Hepatology.2022; 16(5): 449.     CrossRef
  • Morphomolecular Classification Update on Hepatocellular Adenoma, Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma
    Venkata S. Katabathina, Lokesh Khanna, Venkateswar R. Surabhi, Marta Minervini, Krishna Shanbhogue, Anil K. Dasyam, Srinivasa R. Prasad
    RadioGraphics.2022; 42(5): 1338.     CrossRef
  • 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

    Clinical and Molecular Hepatology.2022; 28(4): 583.     CrossRef
  • 2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

    Korean Journal of Radiology.2022; 23(12): 1126.     CrossRef
  • Histomorphological Subtypes of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: Review and Update
    Yoon Jung Hwang, Haeryoung Kim
    AJSP: Reviews and Reports.2022; 27(6): 234.     CrossRef
  • Pediatric Primary Hepatic Tumors: Diagnostic Considerations
    Bryony Lucas, Sanjita Ravishankar, Irina Pateva
    Diagnostics.2021; 11(2): 333.     CrossRef
  • A Case of Lymphocyte-Rich Hepatocellular Carcinoma in a Patient Who Was Treated for Colon Cancer
    Jae Won Song, Ho Soo Chun, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Young Nyun Park, Dai Hoon Han, Do Young Kim
    Journal of Liver Cancer.2021; 21(1): 69.     CrossRef
  • HCC You Cannot See
    Vaishnavi Boppana, Sakshi Sahni, Joseph Glass, Christopher Chang, Denis M McCarthy
    Digestive Diseases and Sciences.2021; 66(7): 2185.     CrossRef
  • An update on subtypes of hepatocellular carcinoma: From morphology to molecular
    Monika Vyas, Dhanpat Jain
    Indian Journal of Pathology and Microbiology.2021; 64(5): 112.     CrossRef
  • HCC: role of pre- and post-treatment tumor biology in driving adverse outcomes and rare responses to therapy
    Sandeep Arora, Roberta Catania, Amir Borhani, Natally Horvat, Kathryn Fowler, Carla Harmath
    Abdominal Radiology.2021; 46(8): 3686.     CrossRef
  • Gadoxetate-enhanced MRI Features of Proliferative Hepatocellular Carcinoma Are Prognostic after Surgery
    Hyo-Jin Kang, Haeryoung Kim, Dong Ho Lee, Bo Yun Hur, Yoon Jung Hwang, Kyung-Suk Suh, Joon Koo Han
    Radiology.2021; 300(3): 572.     CrossRef
  • Radiologic Diagnosis of Hepatocellular Carcinoma
    Woo Kyoung Jeong
    The Korean Journal of Gastroenterology.2021; 78(5): 261.     CrossRef
  • Update on Hepatocellular Carcinoma: a Brief Review from Pathologist Standpoint
    Nese Karadag Soylu
    Journal of Gastrointestinal Cancer.2020; 51(4): 1176.     CrossRef
Close layer
Evaluation of the Outcome after Transarterial Chemoembolization; Refinement of Barcelona Clinic Liver Cancer Stage-B from Eastern Point of View
Namiki Izumi
J Liver Cancer. 2016;16(1):7-11.   Published online March 31, 2016
DOI: https://doi.org/10.17998/jlc.16.1.7
  • 1,373 Views
  • 12 Downloads
AbstractAbstract PDF
Transarterial chemoembolization (TACE) is recommended as the first line treatment option for the patients with Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma (HCC), however, treatment strategy and evaluation of effects after TACE has not been fully established. Recently, sub-stage of BCLC stage B has been proposed and validated, but it should be validated including a large number of the patients and its refinement should be discussed. We have validated the sub-stage of BCLC stage B (B1-B4) by comparing overall survival after TACE, and there was no statistically significant difference in overall survival after TACE between B1 and B2. After excluding the patients with Child-Pugh point 7 from B1, the overall survival was significantly better than that of B2. Therefore, up-to-seven criteria is shown to be a reliable tool for the treatment strategy in the patients with intermediate stage of HCC. Refinement of sub-stage of BCLC stage B has been proposed by some other institutes, and it is important to establish novel treatment strategy for the patients with BCLC stage B after TACE to improve the prognosis of the patients after TACE, and to define the best timing for conversion to sorafenib or liver transplantation should be discussed. (J Liver Cancer 2016;16:7-11)
Close layer
Case Report
A Case of Rapid Progressive Extrahepatic Metastasis of Hepatocellular Carcinoma after Surgical Resection for Huge Single Mass
Eun Sun Jang, Haeryoung Kim, Young Rok Choi, Jai Young Cho, Yoo-Seok Yoon, Ho-Seong Han, Ji Hyun Kim, Jin-Wook Kim, Sook-Hyang Jeong
J Liver Cancer. 2016;16(1):42-46.   Published online March 31, 2016
DOI: https://doi.org/10.17998/jlc.16.1.42
  • 949 Views
  • 14 Downloads
AbstractAbstract PDF
Hepatocellular carcinoma (HCC) shows a poor prognosis with high recurrence rate even after surgical resection. To improve prognosis of HCC patient, regular surveillance for high-risk group is recommended, but cost-benefit of the surveillance under 40 years old Asian male with hepatitis B infection is unclear. We share a 39-year-old male case which showed early recurrence and rapid extrahepatic metastasis after surgical resection for single huge HCC. Based on the pathologic finding, this case was diagnosed with ‘stemness’-related markerexpressing HCC. Further molecular classification for HCC could be beneficial to estimate individual risk for HCC recurrence and to predict prognosis.
Close layer
Original Article
Subclassification of Hepatocellular Carcinoma with Barcelona Clinic Liver Cancer Intermediate Stage
Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Snag Hoon Ahn, Kwang-Hyub Han, Beom Kyung Kim
J Liver Cancer. 2016;16(1):17-22.   Published online March 31, 2016
DOI: https://doi.org/10.17998/jlc.16.1.17
  • 1,434 Views
  • 15 Downloads
AbstractAbstract PDF
Background/Aims
Hepatocellular carcinoma (HCC) with Barcelona Clinic Liver Cancer (BCLC) intermediate stage includes a highly heterogeneous population. Here, we aimed to subclassify hepatocellular carcinoma with BCLC intermediate stage for better prognostification.
Methods
Between 2003 and 2008, 325 patients who were newly diagnosed as HCC with BCLC intermediate stage were considered eligible. Tumor factor and liver function were used for sub-classification. Overall survival (OS) was analyzed using Kaplan-Meier method with a comparison by log-rank test.
Results
A total of 325 patients with intermediate stage HCC were analyzed. Patients with tumor size ≥7 cm, tumor number ≥4 and Child-Pugh class B had the worse OS compared to those with tumor size <7 cm, tumor number <4 and Child-pugh class A, respectively (all P<0.05). These three variables affected the OS independently from multivariate Cox regression analysis (all P<0.05). So, using these three variables, patients were finally sub-classified as those with fulfilling none of three factors (B-a), one of three factors (B-b), two of three factors (B-c) and all of three factors (B-d) with the median OS of 39.2, 20.6, 12.0 and 8.3 months with statistical significances (all P<0.05 between B-a and B-b, between B-b and B-c, and between B-c and B-d), respectively.
Conclusions
Sub-classification of HCC with BCLC intermediate stage may be useful in not only prognostification but also guidance of treatment strategies. (J Liver Cancer 2016;16:17-22)
Close layer

JLC : Journal of Liver Cancer